Photocure ASA Reports Q2 2026 Financial Results
Photocure ASA announced its financial results for the second quarter of 2026. Revenue from Hexvix®/Cysview® reached NOK 140.0 million.
Oslo, Norway – Photocure ASA (OSE: PHO) today reported its financial results for the second quarter of 2026. The company generated NOK 140.0 million in revenue from its Hexvix®/Cysview® products, an increase from NOK 135.6 million reported in the second quarter of 2025.
The adjusted EBITDA for the quarter was NOK 27.2 million, largely in line with the NOK 27.0 million reported in Q2 2025. Detailed financial statements provide further insight into the company's performance during the period.
Photocure specializes in medical devices and software aimed at improving cancer diagnosis and treatment. Hexvix and Cysview are key products in the diagnosis and treatment of bladder cancer.
The company's report focused on the financial performance of its core product lines, offering a snapshot of its operational results for the quarter.